Management of the Older Person With Atrial Fibrillation
Open Access
- 1 June 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 57 (6) , M352-M363
Abstract
Atrial fibrillation (AF) is associated with a higher incidence of mortality, stroke, and coronary events than is sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current (DC) cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, verapamil, or diltiazem may be given to slow immediately a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Nondrug therapies should be performed in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. Paroxysmal AF associated with the tachycardia-bradycardia syndrome should be treated with a permanent pacemaker in combination with drugs. A permanent pacemaker should be implanted in patients with AF and with symptoms such as dizziness or syncope associated with ventricular pauses greater than 3 seconds that are not drug-induced. Elective DC cardioversion has a higher success rate and a lower incidence of cardiac adverse effects than does medical cardioversion in converting AF to sinus rhythm. Unless transesophageal echocardiography has shown no thrombus in the left atrial appendage before cardioversion, oral warfarin should be given for 3 weeks before elective DC or drug cardioversion of AF and should be continued for at least 4 weeks after maintenance of sinus rhythm. Many cardiologists prefer, especially in older persons, ventricular rate control plus warfarin rather than maintaining sinus rhythm with antiarrhythmic drugs. Digoxin should not be used to treat patients with paroxysmal AF. Patients with chronic or paroxysmal AF at high risk for stroke should be treated with long-term warfarin to achieve an International Normalized Ratio of 2.0 to 3.0. Patients with AF at low risk for stroke or with contraindications to warfarin should receive 325 mg of aspirin daily.Keywords
This publication has 118 references indexed in Scilit:
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillationAmerican Heart Journal, 1996
- Left atrial appendage “stunning” after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiographyAmerican Heart Journal, 1995
- Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%The American Journal of Cardiology, 1994
- Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)The American Journal of Cardiology, 1994
- Pacemaker therapy in patients with atrial fibrillationAmerican Heart Journal, 1993
- Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutterThe American Journal of Cardiology, 1989
- The Natural History of Lone Atrial FibrillationNew England Journal of Medicine, 1987
- Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: A multicenter double-blind clinical trialAmerican Heart Journal, 1985
- Epidemiologic Features of Chronic Atrial FibrillationNew England Journal of Medicine, 1982